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Microsatellite repeat expansions cause several incurable and lethal neurodegenerative disorders including 
ataxias, myotonic dystrophy, Huntington's disease and C9ORF72-linked amyotrophic lateral sclerosis (ALS) and 
frontotemporal dementia (FTD). Abnormal repeat transcripts generated from the expanded loci are substrates 
of repeat-associated non-AUG (RAN) translation, an unconventional form of translation leading to the 
production of polymeric repeat proteins with cytotoxic and aggregating properties. The mechanisms involved in 
the pathogenesis of microsatellite repeat expansion disorders remain a hotly debated topic. They are shared 
between toxic loss/gain of functions due to intranuclear RNA foci that sequesters RNA-binding proteins and 
RAN translation of repeat proteins in the cytoplasm. We recently elucidated the molecular mechanism driving 
the nuclear export of C9ORF72 repeat transcripts and showed for the first time that this pathway can be 
manipulated to confer neuroprotection. Strikingly, we discovered that intron-retaining C9ORF72 repeat 
transcripts hijack the physiological NXF1-dependent export pathway by selective RNA-repeat sequestration of 
SRSF1. Antagonizing SRSF1 and the nuclear export of C9ORF72 repeat transcripts promoted in turn the 
survival of patient-derived motor neurons and suppressed neurodegeneration-associated motor deficits in 
Drosophila (Hautbergue et al. Nature Communications 2017; 8:16063). In this invited Research Highlight review, 
we aim to place this work in the context of our previous studies on the nuclear export of mRNAs, provide a 
summary of the published research and highlight the significance of these findings as a novel therapeutic 
strategy for neuroprotection in C9ORF72-ALS/FTD. In addition, we emphasize that protein sequestration, often 
thought as of inducing loss-of-function mechanisms, can also trigger unwanted protein interactions and toxic 
gain-of-functions. 
Keywords: Amyotrophic lateral sclerosis; Frontotemporal dementia; Neurodegeneration; Microsatellite repeat 
expansions; C9ORF72; RNA nuclear export; SRSF1; NXF1; RAN translation; Therapeutic strategy 
To cite this article: Lydia M. Castelli, et al. SRSF1-dependent nuclear export of C9ORF72 repeat-transcripts: targeting toxic 
gain-of-functions induced by protein sequestration as a selective therapeutic strategy for neuroprotection. Ther Targets Neurol 
Dis 2017; 4: e1619. doi: 10.14800/ttnd.1619. 
Copyright: © 2017 The Authors. Licensed under a Creative Commons Attribution 4.0 International License which allows 
users including authors of articles to copy and redistribute the material in any medium or format, in addition to remix, 
RESEARCH HIGHLIGHT 
Therapeutic Targets for Neurological Diseases 2017; 4: e1619. doi: 10.14800/ttnd.1619; © 2017 by Lydia M. Castelli, et al. 
http://www.smartscitech.com/index.php/ttnd 
 
Page 2 of 10 
 
transform, and build upon the material for any purpose, even commercially, as long as the author and original source are 
properly cited or credited. 
 
C9ORF72-related amyotrophic lateral sclerosis and 
frontotemporal dementia 
Polymorphic GGGGCC (or G4C2) hexanucleotide-repeat 
expansions in intron 1 of the C9ORF72 gene are the most 
common known cause of amyotrophic lateral sclerosis (ALS) 
and frontotemporal dementia (FTD) [1,2], a spectrum of 
incurable and fatal adult-onset neurodegenerative diseases. 
FTD involves loss of neurons in the frontal and temporal 
lobes of the cerebral cortex leading to cognitive defects and 
altered personality features such as psychological 
disinhibition. ALS causes selective death of upper and lower 
motor neurons in the motor cortex and spinal cord, resulting 
in muscle atrophy, progressive paralysis and death usually by 
respiratory failure within 3-5 years from symptom onset. A 
proportion of patients with ALS develop FTD, and 
conversely, many patients with FTD will eventually suffer 
from ALS symptoms [3]. Both ALS and FTD-related 
disorders have an annual incidence rate of 1 to 2 per 100,000 
people. Approximately 220,000 cases of patients with ALS 
were recorded across the globe in 2015 and this number is 
projected to increase in an ageing world population up to 
over 370,000 cases by 2040 [4]. Whilst no treatment is 
available for FTD, the current standard of care for ALS 
patients, riluzole, only marginally extends survival and does 
not relieve the symptomatic motor deficits. 
The pathophysiology leading to neuronal injury is 
complex and potentially involves three non-exclusive 
mechanisms of pathogenesis which have been extensively 
studied (reviewed in [5, 6]). These include: (i) RNA toxic 
gain-of-functions by sequestration of RNA-processing 
factors onto hexanucleotide-repeat RNAs, (ii) protein toxic 
gain-of-function due to unconventional repeat-associated 
non-AUG (RAN) translation of cytotoxic dipeptide-repeat 
proteins (DPRs) in all frames and in the absence of canonical 
start codons, and (iii) haploinsufficiency due to reduced 
expression levels of C9ORF72 mRNA and protein. The 
C9ORF72 locus is bi-directionally transcribed leading to 
expression of G4C2-sense and C4G2-antisense transcripts 
which form sense and antisense RNA foci and also lead to 
the RAN translation of sense and antisense DPRs (sense 
poly-Glycine-Alanine, poly-Glycine-Proline, 
poly-Glycine-Arginine and antisense poly-Proline-Arginine, 
poly-Proline-Glycine, poly-Proline-Alanine) [7]. 
We identified that approximately 100 RNA-binding 
factors, including a large proportion of RNA Recognition 
Motif (RRM) containing proteins, are sequestered onto sense 
G4C2-repeat RNA sequences [8]. Among these, we noted 
sequestration of the SR-rich splicing factor (SRSF) and 
nuclear export adaptor proteins SRSF1, SRSF3 and SRSF7 
[9] as well as of the general nuclear export adaptor ALYREF 
(Aly/RNA export factor also known as REF [10]). SRSF1 had 
also been identified as a G4C2-repeat RNA binder in a 
separate study which involved the screening of 
RNA-processing proteins based on their known or predicted 
binding to GC-rich sequences [11]. We hypothesized that the 
sequestration of these nuclear export adaptors might license 
the inappropriate nuclear export of intron-retaining 
C9ORF72 repeat transcripts and subsequently lead to the 
RAN translation of DPRs in the cytoplasm [8]. 
The nuclear export of bulk mRNAs 
The nuclear export of mRNAs is functionally linked to the 
co-transcriptional processing of pre-mRNAs synthesized by 
the RNA polymerase II (RNAPII). RNAPII-dependent 
transcription involves the assembly of a pre-initiation 
complex upstream of the transcription start site (TSS) in the 
promoters of protein-coding genes, following recognition of 
the TATA box element by the TATA box binding protein 
(TBP), a subunit of the general transcription factor TFIID, 
which triggers the recruitment of additional general 
transcription factors and the hypo-phosphorylated form of 
the RNAPII (RNAPIIA). The large subunit of the RNAPII 
exhibits a characteristic carboxyl-terminal domain (CTD) 
constituted by repetitions of the heptapeptide sequence 
YSPTSPS (52 repeats in mammals). Differential 
phosphorylation of the CTD controls the co-transcriptional 
processing of pre-mRNAs upon selective recruitment of 
various RNA-processing protein complexes (reviewed in 
[12]). Serine-5 phosphorylation of the RNAPII CTD by the 
CDK7 kinase subunit of TFIIH promotes the stable initiation 
of transcription initiation whilst the interaction of the capping 
enzyme (CE) with the CTD phosphorylated on serine-5 
residues allows for addition of the CAP at the 5'-end of the 
nascent transcript. Phosphorylation of the RNAPII CTD 
serine-2 residues by the CDK9 kinase subunit of P-TEFb 
(positive transcriptional elongation factor b) is further 
required to maintain the processivity of the 
hyper-phosphorylated form of the RNAPII (RNAPIIO) 
during the elongation phase (reviewed in a special issue [13]). 
Splicing of introns is linked to the deposition of the 
RNA/ATP-dependent DEAD-box RNA helicase 39B 
(DDX39B also known as UAP56 for U2AF65-associated 
protein 56), which promotes the assembly of spliceosomes 
via interactions with the CTD predominantly phosphorylated 
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on serine-2. Different combinations of heterogeneous nuclear 
ribonucleoproteins (hnRNPs) and hyper-phosphorylated 
SRSF factors are involved in the regulation of alternative 
splicing. SRSFs and hnRNPs usually play antagonistic roles 
respectively stimulating and inhibiting the splicing of exons. 
The termination of transcription involves recruitment of the 
cleavage and polyadenylation specificity factor (CPSF) at the 
sequence of core consensus AAUAAA [14] via the RNAPII 
CTD predominantly phosphorylated on serine-2. 
Approximately 200 adenosines are added to the 3'-end of 
human mRNAs. 
mRNAs produced from intron-containing reporter 
constructs are more efficiently exported into the cytoplasm of 
mammalian cells [15]. In human, the vast majority of mRNA 
molecules are exported from the nucleus to the cytoplasm in 
a process that is functionally coupled to splicing via dynamic 
assembly of the evolutionary conserved transcription-export 
complex (TREX) [16]. Interactions of TREX with the 
CAP-binding protein CBP80 at the 5'-end of nascent 
transcripts provide in turn 5' to 3' directionality to the nuclear 
export of mRNAs [17]. TREX is composed of the subcomplex 
THO, DDX39B and the nuclear export adaptor ALYREF [18]. 
Additional factors are associated to TREX including 
interactions with other nuclear export adaptors [19, 20]. The 
interactions of a varied combination of proteins and nuclear 
export adaptors are thought to form substitutes of TREX 
complexes with alternative functionalities and/or mRNA 
selectivity. Direct binding of ALYREF to DDX39B, which 
promotes spliceosome assembly onto the nascent transcript, 
stimulate the ATPase and RNA helicase activities of 
DDX39B leading in turn to the handover of the RNA from 
DDX39B to ALYREF [21]  and recruitment of ALYREF onto 
spliced transcripts prior to the nuclear export process [22]. 
Successive rounds of DDX39B-dependent ATP hydrolysis 
were suggested to facilitate the assembly of TREX by 
loading of proteins with nuclear export adaptor functions [21]. 
Mutually exclusive interactions of ALYREF with DDX39B 
and the nuclear export factor 1 (NXF1, also known as TAP 
[23]) lead to the displacement of DDX39B and handover of 
the RNA molecule from the nuclear export adaptor to NXF1 
by switching NXF1 to a high RNA affinity mode [24] 
following remodeling of NXF1 into an open conformation 
that exposes its RNA-binding domain [25]. The assembly of 
TREX and remodeling of NXF1 is much more complex than 
described here, involving additional proteins, such as nuclear 
export co-adaptors, post-translational modifications and 
dynamic re-arrangements (recently reviewed in [26, 27]). A 
TREX-2 complex, which contains NXF1 and a distinct set of 
proteins, was reported to promote efficient recruitment of 
NXF1 to the nuclear pore complex (NPC) and couple 
transcription to nuclear export, potentially providing a link 
for the nuclear export of intronless transcripts [28, 29]. The 
TREX complex has also been involved in an alternative 
RNA export pathway (AREX) for the NXF1-dependent 
nuclear export of intronless transcripts through direct 
interactions with the CAP-binding complex [30]. 
The direct interactions of NXF1 with the FG-repeat 
regions of some of the nucleoporins, which constitute the 
NPC and protrude in the central channel, further allow 
docking of the mature mRNA-protein complexes and 
transport across the nuclear pore. On the cytoplasmic side of 
the NPC, activation of the DEAD-box RNA helicase Dbp5 
activity (DDX19B in human) by interaction with the 
nucleoporin GLE1 (RNA export mediator) associated to 
inositol hexakisphosphate (IP6) leads to recruitment of 
Dbp5/DDX19B onto the mRNAs promoting the unwinding 
of secondary RNA structures, the displacement of bound 
protein factors and the cytoplasmic release of mRNAs 
(reviewed in [31]). Dissociation of NXF1 from the RNA and 
the nuclear export adaptor is predicted to revert NXF1 into a 
low RNA affinity mode that would also contribute to 
efficient mRNA release [24,32]. It remains unknown whether 
the CAP-dependent translation of mRNAs is linked or not to 
the nuclear export process and/or to the cytoplasmic release. 
Interactions of the eukaryotic initiation translation factor 4F 
(eIF4F), composed of the CAP-binding protein eIF4E, the 
scaffold protein eIF4G and the DEAD box RNA helicase 
eIF4A, in association with the poly(A)-binding protein 
(PABP) allow for circularization and pre-activation of the 
mRNA. The pre-assembled 43S complex comprising the 40S 
small ribosome subunit, the factors eIF1,1A,3,5 and the 
ternary complex eIF2:Met-tRNA is recruited to the activated 
mRNA via interactions with eIF4F to promote scanning of 
the 48S complex through the 5'-untranslated region of the 
mRNA and eIF5B-dependent recruitment of the 60S large 
ribosomal subunit at the AUG start codon for the translation 
of proteins (reviewed in [33, 34]). 
The SR-rich splicing factors SRSF1, SRSF3 and SRSF7 
have also been reported to play a role as nuclear export 
adaptors by directly interacting with the amino-terminal 
domain of NXF1 under a dephosphorylated form upon 
completion of splicing [35]. Like ALYREF, they promote the 
remodeling of NXF1 into a high RNA-binding affinity mode 
that triggers handover of the RNA from the SRSF1,3,7 
proteins to NXF1 [24]. The RNA handover is also facilitated 
by mutually exclusive interactions of the nuclear export 
adaptors with the RNA and NXF1 which both interact with 
arginine residues in unstructured low complexity 
arginine/proline-rich peptides juxtaposed to the RNA 
recognition motifs of ALYREF [24,36], SRSF1 [37] and 
SRSF3/SRSF7 [38]. This led to a model in which the role of 
nuclear export adaptors is to license mRNA nuclear export 
by remodeling NXF1 to a high affinity 
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RNA-binding mode through mutually exclusive interactions 
with RNA and NXF1 on completion of splicing, providing in 
turn a mechanism to retain unprocessed transcripts in the 
nucleus [32]. A simplified diagram represents a summary of 
the human NXF1-dependent nuclear export of the bulk 
mRNAs and its functional coupling to the expression of 
protein-coding genes (Figure 1). 
Several non-essential proteins with mRNA nuclear export 
adaptor functions have been characterised in higher 
eukaryotes. Different adaptors were also found to interact 
with the same transcripts [19]. Depletion of ALYREF is 
dispensable to the nuclear export of bulk mRNAs in 
human and Drosophila cells [19, 39] and to the development 
of nematodes [40]. On the other hand, several of the 
SR-rich splicing factors play an essential role in the 
splicing switch that occurs during development to juvenile 
life. The homozygous deletions of SRSF1 and SRSF3 cause 
Figure 1. Expression of protein-coding genes. The diagram represents an overview of the molecular mechanisms 
involved in the biogenesis and the co-transcriptional processing of RNAPII transcripts with a particular emphasis on the bulk 
nuclear export of human bulk mRNAs which is coupled to splicing via the TREX complex. TREX provides a platform for the 
high RNA-affinity remodeling of NXF1 prior docking to the nuclear pore through interactions of NXF1 with nucleoporins. 
Abbreviations: REF for ALYREF; SRSF for SRSF1 or SRSF3 or SRSF7; NPC for nuclear pore complex. Other nuclear 
export adaptors including UAP56-interacting protein (UIF [19]) and Leucine Zipper Protein 4 (LUZP4 [20]) associate with 
TREX and are likely to play a similar role as ALYREF. 
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embryonic lethality due to failure of the developing heart [41] 
and impaired blastocyst formation [42] respectively. However, 
the depletion of each of the SRSF1-7 proteins in murine cells 
only affect the nuclear export of 0.5-2% of mRNAs despite 
interactions with thousands of transcripts [43]. Taken together, 
the NXF1-dependent nuclear export adaptor function appears 
to involve redundancy and/or cooperation in cultured and 
differentiated cells. 
SRSF1-dependent nuclear export of sense and antisense 
C9ORF72 repeat transcripts  
 As described above, sense C9ORF72 repeat RNA 
expansions sequester ALYREF and SRSF1,3,7 proteins 
letting us hypothesize that increased local concentrations of 
nuclear export adaptors might inappropriately remodel NXF1 
into an high RNA-affinity mode which triggers the nuclear 
export of unspliced C9ORF72 pre-mRNAs retaining repeat 
expansions in intron 1 [8]. In support of this, ALYREF and 
NXF1 have been identified by another group as modifiers of 
the C9ORF72 hexanucleotide-repeat mediated neurotoxicity 
in a Drosophila loss-of-function screen [44]. In the Nature 
Communications study [45] which forms the basis for this 
research highlight review, we showed that 
recombinantly-purified ALYREF and SRSF1 proteins 
directly interact with 5 repetitions of G4C2-sense and 
C4G2-antisense synthetic RNA oligonucleotides. These 
findings are consistent with the co-localisation of ALYREF 
[8] and SRSF1 [45] with nuclear RNA foci in human post 
mortem spinal motor neurons from C9ORF72-ALS cases. To 
investigate the potential involvement of ALYREF and 
SRSF1 in the nuclear export of hexanucleotide repeat 
transcripts which are substrates of cytoplasmic RAN 
translation, we crossed transgenic ALYREF-RNAi and 
SRSF1-RNAi Drosophila lines with flies expressing 36 
uninterrupted G4C2 repeats and exhibiting DPR-mediated 
neurotoxicity [46]. Strikingly, we observed that depletion of 
70-80% SRSF1 mRNAs inhibit the nuclear export of repeat 
transcripts and the subsequent RAN translation of DPRs, 
preventing in turn the rough eye phenotype and the 
neurodegeneration-associated locomotor deficits in both 
larvae and adult flies. In contrast, similar depletion levels of 
ALYREF did not show significant rescue of 
neurodegeneration and motor function. The partial depletion 
of SRSF1 specifically affects G4C2-repeat transcripts since it 
had no effect on dampening the neurotoxicity induced by 
expression of DPRs encoded independently of the 
hexanucleotide repeat sequence. 
Figure 2. Diagrammatic representations of SRSF1 and the NXF1-binding site. SRSF1 wild type (WT) 
represents the full length of SRSF1. It is composed of a short amino-terminal region, a linker flanked by two RNA 
Recognition Motif (RRM) domains and the carboxyl-terminal RS-rich region (Arginine-Serine-rich domain). Amino 
acids composing the NXF1-binding site are highlighted together with the flanking RNA Recognition Motif (RRM) 
domains which constitute the SRSF1 and SRSF1-m4 proteins. The four arginine residues required for the 
interaction with NXF1 are labeled in green whilst alanine substitutions in SRSF1-m4 are shown in purple. Numbers 
represent amino acid position. SRSF1 binds NXF1 as efficiently as SRSF1-WT (+++) while SRSF1-m4 does not (-). 
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We next demonstrated that SRSF1 is sequestered in a 
repeat length dependent manner in neuronal N2A cells using 
reporter sense G4C2x15 / G4C2x38 and antisense C4G2x15 / 
C4G2x39 transcripts that lack canonical AUG start codons 
and Kozak elements to recapitulate the features of RAN 
translation. Since SRSF1 is involved in both splicing and 
nuclear export functions, the reporter constructs were also 
designed without splicing consensus sites or intronic 
sequences to allow for specific investigation of the 
SRSF1-dependent nuclear export potential of G4C2 and 
C4G2 repeat sequences in absence of functional coupling to 
splicing. Interestingly, the expression of uninterrupted 
G4C2x38 or C4G2x39 repeat transcripts which lead to the 
production of DPRs, but not of G4C2/C4G2x15 repeat 
transcripts which do not, is much more potent at inhibiting 
neuronal cell proliferation (by approximately 50%, 48 hours 
post transfection) [45] than transfection (not shown) or stable 
integration [47] of interrupted transcripts harboring 102 
repeats of the G4C2 sequence - in direct correlation with the 
expression levels of DPRs. Depletion of ~70% of the SRSF1 
protein in neuronal N2A cells transfected with the 
DPR-reporter constructs further led to an efficient inhibition 
of the nuclear export and subsequent RAN translation of 
sense/ antisense repeat transcripts which correlated with a 
suppression of the C9ORF72 repeat-mediated cytotoxicity in 
cell proliferation assays. Similar results were obtained in 
primary mouse cortical neurons. The structural and 
functional characterisation of the SRSF1-dependent nuclear 
export function previously showed that 4 arginine residues 
within the unstructured arginine-rich peptide connecting the 
two RNA recognition motifs (RRMs) are required for the 
interaction with NXF1 [37]. Only the de-phosphorylated forms 
of SRSF1,3,7 proteins interact with NXF1 upon completion 
of splicing [35] and the SRSF1 region encompassing the two 
RRMs confers the same NXF1-binding efficiency as wild 
type SRSF1 - the linker peptide constituting the 
NXF1-binding site [37]. Substitution of 4 arginines by 
alanines in the linker region impairs the interaction of 
SRSF1-m4 with NXF1 in both HEK and N2A cells [37,45] 
(Figure 2). In our recent study, we also showed that 
SRSF1-m4 directly interact with G4C2x5 and C4G2x5 
synthetic RNA probes and is sequestered in a length 
dependent manner onto G4C2-sense and C4G2-antisense 
repeat transcripts in neuronal N2A cells. Expression of the 
SRSF1-m4 mutant protein also resulted in nuclear retention 
of the repeat transcripts and in reduced DPR production[45], 
Figure 3. Physiological and pathological nuclear export of C9ORF72 transcripts. The nuclear export of wild type 
C9ORF72 transcripts has not yet been investigated. It might involve recruitment of the TREX complex by uncharacterised 
nuclear adaptor(s) (NEA) and/or coupling to other SR-rich NEAs such as SRSF3 or SRSF7 (SR) during splicing. Strikingly, 
it does not involve SRSF1. The nuclear export of pathological C9ORF72 hexanucleotide-repeat transcripts specifically 
involves RNA-repeat sequestration of SRSF1 and interaction with NXF1. We proposed that the increased local 
concentrations of sequestered SRSF1 inappropriately recruit and remodel NXF1 into a high RNA-affinity mode which 
licenses the nuclear export process. 
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clearly demonstrating that preventing RNA-repeat 
sequestration of endogenous SRSF1 and interaction with 
NXF1 specifically inhibits the nuclear export of synthetic 
reporter repeat transcripts, independently of the splicing 
function of SRSF1. 
To validate these findings in the context of pathological 
C9ORF72 repeat transcripts in human disease, we 
differentiated neurons and motor neurons from 
induced-neural progenitor cells (iNPCs) reprogrammed using 
sex/age-matched control and C9ORF72-ALS patient 
fibroblast biopsies [48]. Pathological C9ORF72 repeat 
transcripts retaining intron-1 were indeed found to 
accumulate in the cytoplasm while unspliced forms of the 
wild type C9ORF72 transcripts were normally retained in the 
nucleus. Our data further showed that the partial depletion of 
SRSF1 does not affect the physiological unspliced fraction of 
wild type C9ORF72 transcripts but selectively inhibits the 
nuclear export of expanded C9ORF72 repeat transcripts in 
correlation with reduced RAN translation of DPRs and an 
increased survival of motor neurons. In contrast, the 
depletion of SRSF1 had no effect on the expression levels, 
splicing of intron-1 or nuclear export of C9ORF72 transcripts 
which encode the wild type C9ORF72 protein. The 
mechanisms involved in the nuclear export of wild type 
C9ORF72 transcripts have not been investigated in this study 
and remain unknown. Significantly, they do not involve 
SRSF1. In summary, a simplified diagram represents our 
findings regarding the nuclear export of wild type and 
pathological C9ORF72 transcripts (Figure 3).  
Manipulating the nuclear export pathway as a novel 
therapeutic strategy for neuroprotection 
A growing body of evidence implicate DPRs as one of the 
primary drivers of pathogenesis in cellular and animal 
models of C9ORF72-ALS/FTD [46, 49-51]. Our work clearly 
reinforces this concept using an unbiased approach of 
investigation which did not rely on modifying expression 
levels or repeat-length of repeat transcripts but rather on 
selectively manipulating transport across the nuclear pore to 
either promote nuclear retention of transcripts or production 
of DPRs. The increased number of nuclear RNA foci upon 
SRSF1 depletion did not appear to induce cytotoxicity in 
neuronal cell models (not shown) or astrocytes in agreement 
with another study in Drosophila [51]. While no detrimental 
effects of SRSF1 depletion were observed in neuronal cells 
or patient-derived neurons, the reduced RAN translation of 
DPRs specifically led to decreased cytotoxicity and to 
neuroprotection of C9ORF72-ALS Drosophila and 
Figure 4. Therapeutic strategies to inhibit the nuclear export of pathological C9ORF72 repeat transcripts.  Our 
research identified two novel therapeutic strategies for neuroprotection which include the partial depletion of SRSF1 or the 
expression of the engineered SRSF1-m4 protein which is specifically sequestered onto C9ORF72 repeat transcripts but 
fails to efficiently recruit NXF1. Importantly, these interventions do not affect the expression levels, the splicing or the 
nuclear export of intron-1-spliced C9ORF72 transcripts which lead to translation of the wild type C9ORF72 protein. 
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patient-derived motor neurons co-cultured with astrocytes. 
Significantly as a potential therapeutic strategy, the 
neuroprotection conferred by the depletion of SRSF1 was 
functionally linked to a suppression of the C9ORF72 
repeat-associated motor deficits in adult Drosophila. ALS 
astrocytes were also reported to be toxic on their own to 
primary and differentiated mouse motor neurons via non-cell 
autonomous mechanisms [48]. Interestingly, while the 
depletion of SRSF1 in astrocytes had no effect in control 
co-culture systems, it specifically reduced the 
C9ORF72-ALS patient-derived astrocyte-mediated 
neurotoxicity promoting in turn the survival of control motor 
neurons in a mechanism that has not yet been investigated. 
Nonetheless, antagonizing the SRSF1 function therefore 
appears to promote survival of motor neurons through two 
pathways that involve inhibiting the RAN translation of 
DPRs and dampening the astrocytic-mediated neurotoxicity. 
Identifying the detailed mechanisms driving the nuclear 
export of repeat transcripts and manipulating their transport 
across the nuclear pore might constitute a valid approach for 
dissecting the complex mechanisms of pathogenesis and 
develop therapeutic strategies in other microsatellite repeat 
expansion disorders. In particular, our study revealed that 
RNA-repeat sequestration of SRSF1 confers toxic 
gain-of-functions by tricking a physiological nuclear export 
adaptor and evading the normal nuclear retention 
mechanisms of unspliced transcripts, which further lead to 
RAN translation of cytotoxic DPRs in the cytoplasm. Since 
the sequestration of SRSF1 is specific to pathological 
C9ORF72 repeat transcripts, it provides a rare opportunity 
for a selective therapeutic strategy using gene therapy 
approaches that would either aim at depleting SRSF1 or at 
expressing the engineered SRSF1-m4 protein (Figure 4). 
Both strategies efficiently inhibited the nuclear export of 
C9ORF72 repeat transcripts and prevented DPR-mediated 
cytotoxicity in neuronal cell models. However, the safety of 
such interventions remains to be tested in vivo in wild type 
animals such as in mice for example. Expression of SRSF1 is 
essential to the development of the heart during embryonic 
development and no study so far has been reported on the 
effects of partial depletion of SRSF1 in the central nervous 
system during adulthood. The expression of the SRSF1-m4 
protein might present an advantage over the partial depletion 
of SRSF1 as it does not involve altering the physiological 
levels of SRSF1 and is sequestered onto RNA-repeats in 
place of the endogenous SRSF1 protein. Other alternative 
therapeutic strategies also include preventing the 
de-phosphorylation of SRSF1 by protein phosphatase 1 
(PP1) or promoting its SRSF protein kinase 1 
(SRPK1)-dependent phosphorylation to inhibit interaction 
with NXF1. 
Perspectives 
We are now evaluating the safety and efficacy of SRSF1 
depletion and SRSF1-m4 expression in wild type and 
C9ORF72-ALS/FTD mice using adeno-associated gene 
therapy approaches through intrathecal or cisterna magna 
delivery in the central nervous system. Antisense 
oligonucleotide (ASO) therapy to knock down SRSF1 is also 
considered as a possible therapeutic strategy since 
controlling the virally induced depletion level of SRSF1 
might be challenging particularly in patients. Gene therapy 
approaches are indeed getting closer and closer to becoming 
valid therapeutic strategies in the clinic as highlighted by the 
recent ASO clinical trials to deplete SOD1 in SOD1-related 
ALS [52] and the very promising replacement of the SMN 
(Survival Motor Neuron) gene using single-dose injection of 
adeno-associated AAV9 viral vectors in babies with spinal 
muscular atrophy [53], a juvenile form of motor neuron 
disease. 
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initiation translation factor; FTD: frontotemporal dementia; 
G4C2: GGGGCC; GLE1: RNA export mediator; IP6: 
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NXF1: nuclear export factor 1; hnRNPs: heterogeneous 
nuclear ribonucleoproteins; PABP: poly(A)-binding protein; 
P-TEFb: positive transcriptional elongation factor b; RAN: 
repeat-associated non-AUG; SRSF, Serine/Arginine-rich 
splicing factor; RRM: RNA recognition motif; RNAPII: 
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TATA box binding protein; TREX: transcription-export 
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